Keyphrases
Chronic Myeloid Leukemia
100%
Early Response
100%
Imatinib
100%
Successful Treatment
33%
Cancer Treatment
16%
Lymphoma
16%
Philadelphia Chromosome
16%
Response to Treatment
16%
Unfavorable Outcome
16%
Molecular Targets
16%
Second Malignant Neoplasm
16%
Conventional Therapy
16%
Secondary Malignant Neoplasm
16%
Cytogenetic Aberrations
16%
Long-term Complications
16%
Tyrosine Kinase
16%
Nasopharyngeal Carcinoma
16%
Complete Cytogenetic Remission
16%
Malignant Process
16%
Excellent Response
16%
Pharmacology, Toxicology and Pharmaceutical Science
Imatinib
100%
Chronic Myeloid Leukemia
100%
Malignant Neoplasm
50%
Remission
16%
Nasopharynx Carcinoma
16%
Protein Tyrosine Kinase
16%
Molecular Target
16%
Philadelphia 1 Chromosome
16%
Medicine and Dentistry
Chronic Myelogenous Leukemia
100%
Imatinib
100%
Malignant Neoplasm
33%
Cancer Therapy
16%
Nasopharynx Carcinoma
16%
Protein Tyrosine Kinase
16%
Philadelphia 1 Chromosome
16%
Biochemistry, Genetics and Molecular Biology
Myeloid
100%
Imatinib
100%
Cytogenetics
33%
Philadelphia Chromosome
16%
Receptor Tyrosine Kinase
16%
Tyrosine Kinase
16%